Spots Global Cancer Trial Database for Niraparib in Combination With Dostarlimab in Patients With Recurrent or Progressive Cervix Cancer

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Niraparib in Combination With Dostarlimab in Patients With Recurrent or Progressive Cervix Cancer

Official Title: Phase II Trial of Niraparib in Combination With Dostarlimab in Patients With Recurrent or Progressive Cervix Cancer (OU-SCC-STAR)

Study ID: NCT04068753

Conditions

Recurrent Cervix Cancer

Progressive Cervix Cancer

Interventions

Niraparib

dostarlimab

Study Description

Brief Summary: The purpose of this research study is to test the safety of Niraparib and dostarlimab as a combination treatment and see what effects (good and bad) this combination treatment has on patients with recurrent or progressive cervix cancer.

Detailed Description: Patients will have tests and exams to see if they are eligible for the clinical trial. If found eligible, the patient will receive treatment with Niraparib daily and dostarlimab by vein every three weeks for 4 cycles then every six weeks. Patients will receive the study treatment as long as there is evidence that the tumor is not growing or spreading and they are not having any unacceptable, bad side effects. Patients will be monitored during treatment with tests and exams and after treatment completion for up to 5 years.